Ryzneuta

What Is Ryzneuta and What Is It Used For?

Ryzneuta belongs to the pharmacological class of granulocyte colony-stimulating factors, known by the abbreviation G-CSF. These biological medicines are structurally similar to a naturally occurring cytokine in the human body that regulates the production, maturation, and release of neutrophils — the most abundant type of white blood cell and the body's frontline defense against bacterial and fungal infections. When neutrophil counts fall dangerously low during cytotoxic cancer treatment, a condition called neutropenia, the risk of life-threatening infection rises sharply. G-CSF therapy reverses this vulnerability by stimulating the bone marrow to produce new neutrophils faster and in greater numbers.

What distinguishes Ryzneuta from first-generation G-CSFs such as filgrastim is its engineered long-acting design. The active substance, efbemalenograstim alfa, is a recombinant fusion protein in which a molecule of human G-CSF is covalently linked to the fragment crystallizable (Fc) portion of a human immunoglobulin G2 (IgG2) antibody. This Fc domain recycles through the neonatal Fc receptor (FcRn) in vascular endothelial cells, dramatically extending the molecule's half-life in circulation. The practical consequence is that a single injection provides sustained G-CSF activity across the entire chemotherapy cycle, eliminating the need for the daily injections required by short-acting filgrastim products, which typically must be given for 7 to 14 consecutive days.

The molecular strategy of Ryzneuta is similar in purpose to pegfilgrastim, another widely used long-acting G-CSF in which filgrastim is chemically modified by the attachment of a polyethylene glycol (PEG) chain to delay renal clearance. Efbemalenograstim alfa takes a different biotechnological route: instead of chemical PEGylation, the extended duration of action is achieved by genetic fusion with an IgG Fc fragment. Clinical pharmacokinetic studies have confirmed that a single 20 mg dose of Ryzneuta produces plasma concentrations and neutrophil support comparable to pegfilgrastim across a full three-week chemotherapy cycle.

Ryzneuta is manufactured using recombinant DNA technology in a mammalian cell expression system, which allows proper protein folding and post-translational modifications such as glycosylation. Because it is a complex biological medicine produced from living cells, Ryzneuta is regulated as a biologic rather than a small-molecule drug, and its approval is based on robust comparative clinical trials demonstrating non-inferiority to established long-acting G-CSF reference products. The U.S. Food and Drug Administration (FDA) granted approval to Ryzneuta in November 2023 for the prevention of chemotherapy-induced febrile neutropenia, and regulatory submissions have been made to other international authorities.

Approved Indications

The approved indication for Ryzneuta in adult patients is narrower and more specifically defined than the indications for short-acting filgrastim products. This reflects the clinical development strategy of long-acting G-CSFs, which are optimized for once-per-cycle prophylaxis rather than daily dosing flexibility.

• Prevention of chemotherapy-induced febrile neutropenia (primary prophylaxis): Ryzneuta is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies (i.e., solid tumors and most lymphomas) who receive myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. Primary prophylaxis is the administration of G-CSF from the first cycle of chemotherapy onward, before neutropenia occurs.
• Prevention of febrile neutropenia (secondary prophylaxis): Ryzneuta may also be used as secondary prophylaxis in patients who experienced febrile neutropenia or dose-limiting neutropenia in a previous chemotherapy cycle, to avoid dose reductions or treatment delays that could compromise cancer control.

Clinical practice guidelines from the American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO), and the National Comprehensive Cancer Network (NCCN) generally recommend primary G-CSF prophylaxis when the expected risk of febrile neutropenia for a given chemotherapy regimen exceeds approximately 20%, or when individual patient risk factors (age, prior neutropenic events, comorbidities) increase the overall risk to a similar threshold. Long-acting agents such as Ryzneuta are typically preferred over short-acting products for most 2- and 3-weekly chemotherapy regimens because of the reduced number of injections and improved compliance.

Ryzneuta is not approved for the treatment of existing neutropenia or for the mobilization of peripheral blood stem cells. Unlike short-acting filgrastim, it is also not indicated for the treatment of severe chronic neutropenia, HIV-associated neutropenia, or to support bone marrow transplantation. Prescribing is typically performed by oncologists or hematologists as part of a structured supportive care plan.

What Should You Know Before Taking Ryzneuta?

Prior to the first dose of Ryzneuta, your healthcare provider will conduct a comprehensive assessment of your medical history, concurrent medications, and planned chemotherapy regimen. Several pre-existing conditions and clinical circumstances can influence both the safety and the appropriateness of long-acting G-CSF therapy, and transparent communication with your oncology team is essential. You should provide details of all prescription medicines, over-the-counter products, herbal remedies, and any previous adverse reactions to biological medicines, growth factors, or PEGylated products.

Contraindications

Ryzneuta is contraindicated in patients with a history of serious allergic reactions to efbemalenograstim alfa, to other G-CSF products (including filgrastim, pegfilgrastim, or any of their biosimilars), or to any of the excipients in the formulation. Allergic reactions to G-CSFs can include anaphylaxis, angioedema, urticaria, and bronchospasm, and such reactions may be fatal if not treated promptly. A documented history of hypersensitivity to PEGylated biologics does not automatically contraindicate Ryzneuta, because Ryzneuta is not PEGylated; however, caution is still warranted, and such patients should be evaluated on a case-by-case basis by an allergy specialist.

Ryzneuta must not be administered to increase the dose intensity or the dose density of chemotherapy regimens beyond established, evidence-based protocols. G-CSF does not mitigate the non-hematological toxicities of chemotherapy — it does not prevent cardiac, pulmonary, neurological, or renal injury from cytotoxic agents — so using G-CSF to push chemotherapy doses higher than those proven safe risks increasing these other toxicities without a corresponding benefit.

Warnings and Precautions

A number of important warnings and precautions apply to the use of Ryzneuta. These are derived from class-wide experience with G-CSF products and from the specific safety database for efbemalenograstim alfa. Your oncology team will consider each of these risks before prescribing and will establish a monitoring plan appropriate to your individual circumstances.

Additional class-wide precautions include the risk of capillary leak syndrome, a potentially life-threatening condition characterized by hypotension, hypoalbuminemia, hemoconcentration, and generalized edema. Episodes of capillary leak syndrome have been reported within days of G-CSF administration and require prompt symptomatic management and hospitalization. Glomerulonephritis has also been reported in patients receiving G-CSF products, typically resolving after dose reduction or discontinuation but occasionally requiring systemic treatment.

Aortitis, or inflammation of the aorta, has been reported rarely in patients receiving G-CSF, generally appearing within the first week of therapy. Presentations may include fever, abdominal pain, malaise, back pain, and elevated inflammatory markers. If aortitis is suspected, Ryzneuta should be discontinued. Thrombocytopenia can occur, particularly in patients receiving concomitant myelosuppressive chemotherapy, and routine complete blood counts with platelet counts are recommended during each cycle. Leukocytosis, with white blood cell counts exceeding 100 × 10⁹/L, has been observed in rare cases following G-CSF administration; no direct adverse events have been consistently attributed to this leukocytosis, but marked elevations should prompt reassessment of dosing.

Potential for tumor growth stimulation is a theoretical concern with G-CSF because the G-CSF receptor is expressed on some myeloid malignancies and has been detected on a subset of non-myeloid tumor cell lines. Ryzneuta is approved only for patients with non-myeloid cancers, and it should not be used in patients with myeloid malignancies such as acute myeloid leukemia. The long-term safety of G-CSF in patients with chronic myelogenous leukemia and myelodysplastic syndromes has not been established. The risk of secondary myeloid malignancies with long-term G-CSF use appears to be low but should be considered in the overall risk-benefit assessment.

Pregnancy and Breastfeeding

There are no adequate and well-controlled studies of efbemalenograstim alfa in pregnant women. Based on data from other G-CSF products and animal reproduction studies, G-CSFs crossed the placenta at high doses and caused reproductive toxicity in laboratory animals, including embryo-fetal loss and decreased birth weight. The potential risks to a human pregnancy are not fully characterized. Ryzneuta should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Pregnant patients who receive Ryzneuta as part of cancer care should be managed by a multidisciplinary team with expertise in oncologic care during pregnancy.

It is unknown whether efbemalenograstim alfa is excreted in human breast milk, whether it is absorbed systemically by a breastfeeding infant, or what effect it might have on the infant. Because many medicines are excreted in human milk and because of the potential for serious adverse reactions in the nursing infant, a decision should be made whether to discontinue nursing or to discontinue Ryzneuta, taking into account the importance of the drug to the mother's cancer treatment. Women of childbearing potential should use effective contraception during treatment and for an appropriate period after the last dose, as advised by their oncology team.

Use in Special Populations

Population pharmacokinetic analyses suggest that age alone does not meaningfully affect the pharmacokinetics of efbemalenograstim alfa in adults. No specific dose adjustment is required for older patients based on age, but older patients may be more sensitive to adverse effects and should be monitored accordingly. Limited data are available in patients with severe hepatic or renal impairment, and clinical judgment should guide use in these populations. Ryzneuta is not approved for use in children and adolescents below 18 years of age; pediatric safety and efficacy have not been established.

How Does Ryzneuta Interact with Other Drugs?

Drug interactions with efbemalenograstim alfa are primarily pharmacodynamic rather than pharmacokinetic. Because Ryzneuta is a large protein that is cleared by receptor-mediated mechanisms and the neonatal Fc receptor pathway, it does not interact with hepatic cytochrome P450 enzymes and has no meaningful direct effect on the metabolism of small-molecule drugs. However, its biological effect — stimulating neutrophil production — creates important timing considerations with cytotoxic cancer therapies and several other agents that affect myeloid cells or that share toxicity profiles.

Patients and caregivers should maintain an up-to-date list of all medicines and supplements and share this list with every clinician involved in cancer care. This includes prescription medicines, over-the-counter products, vitamins, and herbal remedies. The oncology pharmacist plays a particularly important role in identifying potential interactions and optimizing the timing of each medicine in the chemotherapy cycle.

Major Interactions

Minor Interactions

Always inform every member of your healthcare team — including dentists, surgeons, pharmacists, and emergency department clinicians — that you are receiving Ryzneuta during your chemotherapy cycle. This information is relevant both for avoiding medication conflicts and for the interpretation of routine laboratory tests, which can show transient changes related to G-CSF activity. If a new prescription is considered while you are on active chemotherapy, the oncology pharmacist should be consulted before it is dispensed.

What Is the Correct Dosage of Ryzneuta?

Unlike short-acting filgrastim, which is dosed on a weight-based schedule over multiple days, Ryzneuta uses a fixed-dose strategy that simplifies administration and reduces the risk of dosing errors. The fixed dose was selected based on pharmacokinetic and pharmacodynamic studies demonstrating consistent, protective neutrophil support across a representative range of adult body weights. All dosing decisions should be made by the treating oncology physician and cross-checked by the oncology pharmacist as part of the chemotherapy order set.

Adults

Children and Adolescents

Ryzneuta is not approved for use in pediatric patients under 18 years of age. The safety, efficacy, and pharmacokinetic profile of efbemalenograstim alfa in children and adolescents have not been established in adequate clinical trials. In pediatric oncology practice, short-acting filgrastim is the preferred G-CSF for most indications, and long-acting G-CSFs are used selectively based on individual clinical judgment and institutional protocols. Families should consult their pediatric oncology team about the most appropriate supportive care strategy.

Elderly

No dose adjustment based on age is required. In clinical studies, older adults with cancer (65 years and above) experienced benefit and tolerability similar to that of younger adults. However, older patients may have a greater burden of comorbid conditions, concurrent medications, and age-related organ function changes, all of which may influence the overall risk-benefit assessment and the monitoring plan. In very elderly or frail patients, close clinical surveillance for bone pain, dehydration, and infection is advisable.

Renal and Hepatic Impairment

Because efbemalenograstim alfa is a large protein, it is not cleared primarily by hepatic or renal mechanisms in the way small-molecule drugs are. Population pharmacokinetic analyses have not identified a need for dose adjustment in patients with mild to moderate renal or hepatic impairment. Data are limited in severe renal or hepatic impairment, and clinical judgment should be exercised in these populations, with consideration of alternative supportive care strategies if significant concerns exist.

Missed Dose

If a scheduled dose of Ryzneuta is missed, contact the oncology team without delay. Because Ryzneuta is a once-per-cycle injection timed to the completion of chemotherapy, a delayed or missed dose can materially increase the risk of febrile neutropenia. The oncology team will advise on the timing of a catch-up dose based on how many days have elapsed since chemotherapy completion and the anticipated neutrophil nadir. Do not administer an additional dose within the same cycle unless specifically instructed by the treating oncologist.

Overdose

There is limited clinical experience with overdose of efbemalenograstim alfa. In the event of accidental overdose, the most likely consequence is transient leukocytosis, with white blood cell counts potentially rising above the normal range for several days. Patients should be monitored with serial complete blood counts until values return to baseline. Supportive care is the primary management; there is no specific antidote for G-CSF overdose. Clinical complications directly attributable to marked leukocytosis are rare but could theoretically include hyperviscosity, leukostasis with pulmonary or cerebral manifestations, or microvascular complications in patients with predisposing comorbidities.

What Are the Side Effects of Ryzneuta?

Like all medicines, Ryzneuta can cause side effects, although not everyone will experience them. The side effect profile of efbemalenograstim alfa is broadly consistent with the well-characterized class effects of G-CSF agents, which have been studied extensively over more than three decades of clinical use worldwide. Most side effects observed in clinical trials of Ryzneuta were mild to moderate in severity, manageable with standard supportive care, and did not require discontinuation of therapy.

When interpreting the side effect profile of any G-CSF used during cancer treatment, it is important to distinguish effects caused by the growth factor from symptoms caused by the underlying malignancy or the chemotherapy itself. Large randomized trials comparing G-CSFs to placebo or to each other help clarify which effects are specifically attributable to G-CSF. The frequency categories below follow the standard MedDRA convention used by the European Medicines Agency (EMA) and reflect pooled data from Ryzneuta clinical trials and pharmacovigilance reports from the G-CSF drug class.

Clinicians and patients should recognize the distinctive presentation of splenic rupture, which, although rare, is a surgical emergency. Suggestive features include sudden left upper quadrant abdominal pain, pain radiating to the left shoulder tip (Kehr's sign), dizziness from blood loss, and a drop in blood pressure. Immediate emergency department evaluation with abdominal imaging is indicated.

If you experience any side effect, whether listed here or not, report it to your oncology team, a pharmacist, or a nurse. Side effects can also be reported directly to national pharmacovigilance authorities, such as the FDA MedWatch program in the United States or equivalent agencies in other countries. Pharmacovigilance reporting contributes to the continuous refinement of safety information for biologic medicines such as Ryzneuta.

How Should You Store Ryzneuta?

Proper handling and storage of Ryzneuta are essential to preserve the integrity of this protein-based biological medicine. Fc-fusion proteins, like other therapeutic biologics, are susceptible to physical and chemical degradation when exposed to temperature extremes, mechanical agitation, or light over prolonged periods. Incorrect storage can lead to loss of biological activity or, in rare cases, the formation of protein aggregates that may affect tolerability.

Ryzneuta pre-filled syringes should be stored in a refrigerator at 2–8°C (36–46°F). The product must not be frozen. If a syringe is accidentally frozen, it should be discarded and not used, as freezing can induce irreversible conformational changes in the fusion protein. Keep the syringes in the original outer carton until use to shield them from light exposure. Do not store the product near the freezer compartment or the rear cooling elements of the refrigerator, which can reach sub-zero temperatures intermittently.

For patient and caregiver convenience, the syringe may be removed from the refrigerator and kept at room temperature, not above 25°C (77°F), for a single continuous period of up to 72 hours. Allowing the syringe to come to room temperature before injection (typically 15 to 30 minutes out of the refrigerator) can reduce injection site discomfort. If Ryzneuta is not administered within this 72-hour room-temperature window, it must be discarded. Do not return a syringe to the refrigerator once it has been stored at room temperature.

Before administration, visually inspect the solution through the transparent viewing area of the syringe. The liquid should be clear and colorless to slightly yellowish and free of visible particulate matter. Do not use the product if it appears cloudy, discolored, or contains particles. Do not shake the syringe vigorously at any time, as shaking can induce protein aggregation. Gentle swirling is acceptable if any settling is observed.

Keep Ryzneuta and all medicines out of the sight and reach of children. Do not use after the expiry date printed on the carton and syringe label; the expiry date refers to the last day of the indicated month. Used syringes and any unused medicine should be disposed of in a designated sharps container in accordance with local healthcare waste regulations. Do not discard needles or syringes in household waste. Your pharmacist or home care nurse can advise on safe sharps disposal options available in your area.

What Does Ryzneuta Contain?

Understanding the composition of Ryzneuta is important for identifying potential allergens, managing patients with specific dietary or metabolic sensitivities, and ensuring that injection technique and administration practices are appropriate. Because efbemalenograstim alfa is a biologic medicine, the formulation is carefully designed to protect the conformation and biological activity of the fusion protein across the shelf life of the product.

Active Substance

Each 1.0 mL pre-filled syringe contains 20 mg of efbemalenograstim alfa, a recombinant fusion protein composed of human granulocyte colony-stimulating factor (G-CSF) covalently linked via a short peptide linker to a human immunoglobulin G2 (IgG2) Fc fragment. Efbemalenograstim alfa is produced by recombinant DNA technology in a mammalian cell expression system, which supports the correct folding and post-translational modification of the dimeric protein. The resulting active substance has a molecular weight substantially larger than unmodified G-CSF, contributing to its extended half-life in circulation.

Excipients

The inactive ingredients in Ryzneuta are chosen to maintain the stability of the fusion protein, buffer the pH of the solution, adjust tonicity for subcutaneous injection, and minimize protein aggregation. Typical excipients in Ryzneuta formulations include:

• Buffering agents: A buffer system, commonly based on acetate, histidine, or phosphate salts, to maintain the solution at the pH range optimal for Fc-fusion protein stability
• Stabilizers: A polyol such as sorbitol, mannitol, or trehalose, or an amino acid such as arginine, to stabilize the protein during storage and freeze-drying, where applicable
• Surfactants: A non-ionic surfactant such as polysorbate 20 or polysorbate 80, which prevents surface-induced protein aggregation at the air-liquid and container-liquid interfaces
• Tonicity agents: Sodium chloride or similar agents to render the solution isotonic with plasma for comfortable subcutaneous injection
• Water for injections: The solvent that forms the bulk of the liquid formulation

Ryzneuta does not contain preservatives such as benzyl alcohol or phenol, so each pre-filled syringe is intended for single use only and any unused portion should be discarded after administration. The specific excipient list, including any polyol content relevant to patients with hereditary fructose intolerance, should be reviewed in the current prescribing information or Summary of Product Characteristics for your country. Patients with known hypersensitivity to any component should discuss alternative supportive care strategies with their oncology team before starting therapy. Packaging materials for the pre-filled syringe are latex-free, making Ryzneuta suitable for patients with latex allergy.

References

This article is based on the following peer-reviewed sources and international guidelines:

1. U.S. Food and Drug Administration (FDA). Ryzneuta (efbemalenograstim alfa-vuxw) injection — Prescribing Information. FDA-approved labeling, current version. Available at: www.accessdata.fda.gov
2. European Medicines Agency (EMA). Guidance on the use of granulocyte colony-stimulating factor agents and biological medicines for supportive cancer care. EMA/CHMP, current version. Available at: www.ema.europa.eu
3. Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology. 2015;33(28):3199–3212.
4. Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Annals of Oncology. 2016;27(Suppl 5):v111–v118.
5. Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia. European Journal of Cancer. 2011;47(1):8–32.
6. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Hematopoietic Growth Factors. Version 1.2025.
7. Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. Journal of Clinical Oncology. 2007;25(21):3158–3167.
8. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004;100(2):228–237.
9. Cornes P, Gascon P, Chan S, et al. Systematic Review and Meta-Analysis of Short- versus Long-Acting Granulocyte Colony-Stimulating Factors for Reduction of Chemotherapy-Induced Febrile Neutropenia. Advances in Therapy. 2018;35(11):1816–1829.
10. British National Formulary (BNF). Granulocyte-colony stimulating factor agents. NICE Evidence Services, current edition. Available at: bnf.nice.org.uk
11. World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List (2023). Geneva: WHO; 2023.
12. Weycker D, Barron R, Edelsberg J, et al. Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter? Supportive Care in Cancer. 2016;24(5):2309–2316.

Editorial Team

This article was written and reviewed by the iMedic Medical Editorial Team, composed of licensed specialist physicians with expertise in clinical pharmacology, hematology, and oncology supportive care.

Evidence standard: All medical claims in this article are supported by evidence level 1A (systematic reviews and meta-analyses of randomized controlled trials) or current international clinical practice guidelines. This content has no commercial funding and is free from pharmaceutical industry influence.